This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|January 1, 2021
Cytiva Opens New Manufacturing Facility in Massachusetts
Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.
Advertisement
Cytiva opened its new 80,000-ft2 manufacturing facility in Shrewsbury, MA, the company announced in a Dec. 21, 2020 press release. The new facility will make Xcellerex XDR single-use bioreactors and is part of Cytiva’s $500 million global capacity expansion planned for the next five years. The Shrewsbury site expansion was supported by a Technology Investment Agreement entered in October with the Biomedical Advanced Research and Development Authority (BARDA).
The new facility was built in less than five months to meet demand for the company’s technologies. The building includes five manufacturing lines operating 24/5, a new cleanroom, and an R&D lab. The company is also adding manufacturing lines for complementary single-use technologies at its Westborough, MA facility and expects the capacity expansion to be completed by Q2 2021.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5